Treatment of thromboangiitis obliterans (Buerger’s disease) includes both surgical and nonsurgical approaches, or a combination of both. A definite therapeutic approach has not yet been set. This article reviews the proposed therapeutic strategies and considers the advantages and disadvantages of each treatment. Cessation of smoking seems to be the only globally accepted therapeutic measure to prevent disease progression. A number of promising novel therapeutic strategies may prove useful for the treatment of this physically and socially mutilating disease.
Get full access to this article
View all access options for this article.
References
1.
Buerger L: Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene. Am J Med Sci136: 567-580, 1908.
No YJ, Lee EM, Lee DH, et al: Cerebral angiographic findings in thromboangiitis obliterans. Neuroradiology47: 912-915, 2005.
4.
Hoppe B, Lu JT, Thistlewaite P, et al: Beyond peripheral arteries in Buerger’s disease: angiographic considerations in thromboangiitis obliterans. Catheter Cardiovasc Interv57: 363-366, 2002.
5.
Calguneri M, Ozturk MA, Ay H, et al: Buerger’s disease with multisystem involvement. A case report and a review of the literature. Angiology55: 325-328, 2004.
Rai M, Miyashita K, Oe H, et al: Multiple brain infarctions in a young patient with Buerger’s disease. A case report of cerebral thromboangiitis obliterans. Rinsho Shinkeigaku44: 522-526, 2004.
8.
Matchev S, Petrov V, Batchvarova V, et al: Transcranial Doppler velocities in patients with thromboangiitis obliterans. Angiology48: 535-544, 1997.
Czarnacki M, Zdrojowy K, Adamiec R: Review of current etiopathogenic data of Buerger disease. Pol Merkuriusz Lek13: 263-265, 2002.
14.
Kurata A, Franke FE, Machinami R, et al: Thromboangiitis obliterans: classic and new morphological features. Virchows Arch436: 59-67, 2000.
15.
Corelli F: Buerger’s disease: cigarette smoker disease may always be cured by medical therapy alone. Uselessness of operative treatment. J Cardiovasc Surg (Torino)14: 28-36, 1973.
16.
Hooten WM, Bruns HK, Hays JT: Inpatient treatment of severe nicotine dependence in a patient with thromboangiitis obliterans (Buerger’s disease). Mayo Clin Proc73: 529-532, 1998.
Makita S, Nakamura M, Murakami H, et al: Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger’s disease). Circulation94: II-211-II-215, 1996.
20.
Yamamoto K, Iwase S, Mano T, et al: Muscle sympathetic outflow in Buerger’s disease. J Auton Nerv Syst44: 67-75, 1993.
21.
Iwase S, Okamoto T, Mano T, et al: Skin sympathetic outflow in Buerger’s disease. Auton Neurosci87: 286-292, 2001.
22.
Narkiewicz K, van de Borne PJ, Hausberg M, et al: Cigarette smoking increases sympathetic outflow in humans. Circulation98: 528-534, 1998.
23.
Celermajer DS, Adams MR, Clarkson P, et al: Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med334: 150-154, 1996.
24.
Chalon S, Moreno H Jr, Benowitz NL, et al: Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clin Pharmacol Ther67: 391-397, 2000.
25.
Avcu F, Akar E, Demirkilic U, et al: The role of prothrombotic mutations in patients with Buerger’s disease. Thromb Res100: 143-147, 2000.
26.
Brodmann M, Renner W, Stark G, et al: Prothrombotic risk factors in patients with thromboangiitis obliterans. Thromb Res99: 483-486, 2000.
27.
Kobayashi M, Ito M, Nakagawa A, et al: Immunohistochemical analysis of arterial wall cellular infiltration in Buerger’s disease (endarteritis obliterans). J Vasc Surg29: 451-458, 1999.
28.
Matsushita M, Kuzuya A, Kobayashi M, et al: Buerger’s disease in a 19-year-old woman. J Vasc Surg38: 175-179, 2003.
29.
Olin JW, Young JR, Graor RA, et al: The changing clinical spectrum of thromboangiitis obliterans (Buerger’s disease). Circulation82: IV3-IV8, 1990.
30.
Lau H, Cheng SW: Buerger’s disease in Hong Kong: a review of 89 cases. Aust N Z J Surg67: 264-269, 1997.
31.
Nakajima N: The change in concept and surgical treatment on Buerger’s disease—personal experience and review. Int J Cardiol66: S273-S280, 1998.
32.
Bozkurt AK, Besirli K, Koksal C, et al: Surgical treatment of Buerger’s disease. Vascular12: 192-197, 2004.
33.
Shigematsu H, Shigematsu K: Factors affecting the long-term outcome of Buerger’s disease (thromboangiitis obliterans). Int Angiol18: 58-64, 1999.
34.
Roncon-Albuquerque R, Serrao P, Vale-Pereira R, et al: Plasma catecholamines in Buerger’s disease: Effects of cigarette smoking and surgical sympathectomy. Eur J Vasc Endovasc Surg24: 338-343, 2002.
35.
Brodde OE: Physiology and pharmacology of cardiovascular catecholamine receptors: implications for treatment of chronic heart failure. Am Heart J120: 1565-1572, 1990.
36.
Naik RS, Tripathi BP, Vaidya RC, et al: Buerger’s disease versus adrenalectomy and sympathectomy. J Indian Med Assoc71: 199-202, 1978.
37.
Sayin A, Bozkurt AK, Tuzun H, et al: Surgical treatment of Buerger’s disease: experience with 216 patients. Cardiovasc Surg1: 377-380, 1993.
38.
Sasajima T, Kubo Y, Inaba M, et al: Role of infrainguinal bypass in Buerger’s disease: an eighteen-year experience. Eur J Vasc Endovasc Surg13: 186-192, 1997.
39.
Shindo S, Matsumoto H, Ogata K, et al: Arterial reconstruction in Buerger’s disease: by-pass to disease-free collaterals. Int Angiol21: 228-232, 2002.
40.
Ohta T, Ishioashi H, Hosaka M, et al: Clinical and social consequences of Buerger disease. J Vasc Surg39: 176-180, 2004.
41.
Singh I, Ramteke VK: The role of omental transfer in Buerger’s disease: New Delhi’s experience. Aust N Z J Surg66: 372-376, 1996.
42.
Talwar S, Jain S, Porwal R, et al: Pedicled omental transfer for limb salvage in Buerger’s disease. Int J Cardiol72: 127-132, 2000.
43.
Bhargava JS, Makker A, Bhargava K, et al: Pedicled omental transfer for ischaemic limbs-a 5-year experience. J Indian Med Assoc95: 100-102, 1997.
Stumpflen A, Ahmadi A, Attender M, et al: Effects of transvenous regional guanethidine block in the treatment of critical finger ischemia. Angiology51: 115-122, 2000.
46.
Saha K, Chabra N, Gulati SM: Treatment of patients with thromboangiitis obliterans with cyclophosphamide. Angiology52: 399-407, 2001.
47.
Fiessinger JN, Schafer M: Trial of iloprost versus aspirin treatment for critical limb ischemia of thromboangiitis obliterans: The TAO Study. Lancet335: 555-557, 1990.
48.
The European TAO Study Group: Oral iloprost in the treatment of thromboangiitis obliterans (Buerger’s disease): a double-blind, randomised, placebo-controlled trial. Eur J Vasc Endovasc Surg15: 300-307, 1998.
49.
Paraskevas KI, Trigka AA, Samara M: Successful intravenous regional sympathetic blockade (Bier’s Block) with guanethidine and lidocaine in a patient with advanced Buerger’s Disease (thromboangiitis obliterans)-a case report. Angiology56: 493-496, 2005.
50.
Hussein EA, el Dorri A: Intra-arterial streptokinase as adjuvant therapy for complicated Buerger’s disease: early trials. Int Surg78: 54-58, 1993.
51.
Kawabata H, Kamakura T, Guti A, et al: Successful treatment of digital ulceration in Buerger’s disease with nicotine chewing gum. Br J Derm140: 187-188, 1999.
52.
Rydzewski A, Urano T, Hachiya T, et al: The effect of 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger’s disease. Thromb Res84: 445-452, 1996.
53.
Swigris JJ, Olin JW, Mekhail NA: Implantable spinal cord stimulator to treat the ischemic manifestations of thromboangiitis obliterans (Buerger’s disease). J Vasc Surg29: 928-935, 1999.
54.
Chierichetti F, Mambrini S, Bagliani A, et al: Treatment of Buerger’s disease with electrical spinal cord stimulation—review of three cases. Angiology53: 341-347, 2002.
55.
Manfredini R, Boari B, Gallerani M, et al: Thromboangiitis obliterans (Buerger disease) in a female mild smoker treated with spinal cord stimulation. Am J Med Sci327: 365-368, 2004.
56.
Pace AV, Saratzis N, Karokis D, et al: Spinal cord stimulation in Buerger’s disease. Ann Rheum Dis61: 1114-1114, 2002.
57.
Donas KP, Schulte S, Ktenidis K, et al: The role of epidural spinal cord stimulation in the treatment of Buerger’s disease. J Vasc Surg41: 830-836, 2005.
58.
Isner JM, Baumgartner I, Rauh G, et al: Treatment of thromboangiitis obliterans (Buerger’s disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg28: 964-973, 1998.
59.
Ishida A, Ohya Y, Sakuda H, et al: Autologous peripheral blood mononuclear cell implantation for patients with peripheral arterial disease improves limb ischemia. Circ J69: 1260-1265, 2005.
60.
Inan M, Alat I, Kutlu R, et al: Successful treatment of Buerger’s disease with intramedullary K-wire: the results of the first 11 extremities. Eur J Vasc Endovasc Surg29: 277-280, 2005.
61.
Seibold JR, Allegar NE: The treatment of Raynaud’s phenomenon. Clin Dermatol12: 317-321, 1994.
62.
Sulzberger MB: Hypersensitivity to tobacco glyco-protein in human peripheral vascular disease. Ann Allergy47: 476-476, 1981.
63.
Gulati SM, Madhra K, Thusoo TK, et al: Autoantibodies in thromboangiitis obliterans (Buerger’s disease). Angiology33: 642-651, 1982.
64.
Gulati SM, Saha K, Kant L, et al: Significance of circulatory immune complexes in thromboangiitis obliterans (Buerger’s disease)Angiology35: 276-281, 1984.
65.
Adar R, Papa MZ, Halpern Z, et al: Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med308: 1113-1116, 1983.
66.
Slavov ES, Stanilova SA, Petkov DP, et al: Cytokine production in thromboangiitis obliterans patients: new evidence for an immune-mediated inflammatory disorder. Clin Exp Rheumatol23: 219-226, 2005.
67.
Kroger K, Kreuzfelder E, Moser C, et al: Thromboangiitis obliterans: leucocyte subpopulations and circulating immune complexes. Vasa30: 189-194, 2001.
68.
Maslowski L, McBane R, Alexewicz P, et al: Antiphospholipid antibodies in thromboangiitis obliterans. Vasc Med7: 259-264, 2002.
69.
de Godoy JM, Braile DM, Godoy MF: Buerger’s disease and anticardiolipin antibodies: a worse prognosis? Clin Appl Thromb Hemost8: 85-86, 2002.
70.
Lee T, Seo JW, Sumpio BE, et al: Immunobiologic analysis of arterial tissue in Buerger’s disease. Eur J Vasc Endovasc Surg25: 451-457, 2003.
71.
Mach F: Statins as immunomodulatory agents. Circulation109: II15-II17, 2004.
Bozkurt AK, Koksal C, Ercan M: The altered hemorheologic parameters in thromboangiitis obliterans: a new insight. Clin Appl Thromb Hemost10: 45-50, 2004.
75.
Zheng P, Chen SJ, Shao HZ: Studies on hypercoagulation state in thromboangiitis obliterans. Chin Med J (Engl)102: 67-71, 1989.
76.
Szendro G, Golcman L, Cristal N: Study of the factors affecting blood viscosity in patients with thromboangiitis obliterans. A preliminary report. J Vasc Surg7: 759-762, 1988.
77.
Poliantsev AA, Mozgovoi PV, Frolov DV, et al: Effect of Buerger’s thromboangiitis activity on the outcomes of vascular reconstruction. Angiol Sosud Khir10: 91-96, 2004.
78.
Carr ME Jr, Hackney MH, Hines SJ, et al: Enhanced platelet force development despite drug-induced inhibition of platelet aggregation in patients with thromboangiitis obliterans-two case reports. Vasc Endovascular Surg36: 473-480, 2002.
79.
Pietraszek MH, Choudhury NA, Baba S, et al: Serotonin as a factor involved in pathophysiology of thromboangiitis obliterans. Int Angiol12: 9-12, 1993.
80.
Choudhury NA, Pietraszek MH, Hachiya T, et al: Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger’s disease). Thromb Res66: 321-329, 1992.
81.
Musial J, Wilczynska M, Sladek K, et al: Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins31: 61-70, 1986.
82.
Milionis HJ, Elisaf MS, Mikhailidis DP: The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des9: 2425-2443, 2003.
83.
Brumeanu TD, Goldstein R, Casares S: Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clin Immunol119: 1-12, 2006.
84.
Riboldi P, Gerosa M, Meroni PL: Statins and autoimmune diseases. Lupus14: 765-768, 2005.
85.
Nagashima H, Kasanuki H: Therapeutic value of statins for vascular remodeling. Curr Vasc Pharmacol1: 273-279, 2003.
86.
Calabro P, Yeh ET: The pleiotropic effects of statins. Curr Opin Cardiol20: 541-546, 2005.
Ghajar AW, Miles JB: The differential effect of the level of spinal cord stimulation on patients with advanced peripheral vascular disease in the lower limbs. Br J Neurosurg12: 402-408, 1998.
89.
Claeys LG, Horsch S: Transcutaneous oxygen pressure as predictive parameter for ulcer healing in end-stage vascular patients treated with spinal cord stimulation. Int Angiol15: 344-349, 1996.
90.
Banai S, Jaklitsch MT, Shou M, et al: Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation89: 2183-2189, 1994.
91.
Takeshita S, Zheng LP, Brogi E, et al: Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest93: 662-670, 1994.
92.
Hariawala MD, Horowitz JR, Esakof D, et al: VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res63: 77-82, 1996.
93.
Pu LQ, Sniderman AD, Brassard R, et al: Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation88: 208-215, 1993.
94.
Kim HJ, Jang SY, Park JI, et al: Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp Mol Med36: 336-344, 2004.
95.
Morishita R, Aoki M, Hashiya N, et al: Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension44: 203-209, 2004.
96.
Miyamoto M, Yasutake M, Takano H, et al: Therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease using assessment of neovascularization by 99mTc-tetrofosmin (TF) perfusion scintigraphy. Cell Transplant13: 429-437, 2004.
97.
Tateishi-Yuyama E, Matsubara H, Murohara T, et al; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators: Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet360: 427-435, 2002.
98.
Esato K, Hamano K, Li TS, et al: Neovascularization induced by autologous bone marrow cell implantation in peripheral arterial disease. Cell Transplant11: 747-752, 2002.
99.
Iba O, Matsubara H, Nozawa Y, et al: Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circulation106: 2019-2025, 2002.
